NICE | July 2019 | Innovative treatment for gynaecological cancers approved for Cancer Drugs Fund
NICE has announced that it has approved Olaparib, a medicine that has previously been used at a later stage in the treatment of advanced ovarian cancer, has now been approved by NICE as a first-line maintenance treatment.
Currently around 700 women with advanced ovarian cancer are expected to benefit from this new treatment option. As a maintenance therapy, it is used to prevent the cancer returning after primary treatment. It is taken as a tablet twice-a-day
Director of the NICE Centre for Health Technology Evaluation,Meindert Boysen “The availability of olaparib tablets as maintenance therapy is an important development in the management of BRCA mutation-positive advanced ovarian cancer. Olaparib is already used for ovarian cancer but is expected to have the greatest benefit when used early, and is considered to have the potential to cure the disease in some people if given before the first recurrence.
“We are pleased that the company has agreed a commercial arrangement for olaparib that will allow it to be made available immediately to people who currently have an unmet need for maintenance treatment.”
Read the full news story from NICE
In the news:
The Independent ‘Game- changing’ ovarian cancer drug receives NHS approval